Clinical Trial Detail

NCT ID NCT03239145
Title Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

ovarian cancer

colorectal cancer

melanoma

renal cell carcinoma

Advanced Solid Tumor

Therapies

Pembrolizumab + Trebananib

Age Groups: adult senior

No variant requirements are available.